<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Chemotherapy Resistance &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/chemotherapy-resistance/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 13 Jan 2026 07:50:44 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Chemotherapy Resistance &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Venetoclax plus ML385 defeats AML chemotherapy resistance</title>
		<link>https://bioengineer.org/venetoclax-plus-ml385-defeats-aml-chemotherapy-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 13 Jan 2026 07:50:22 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Chemotherapy Resistance]]></category>
		<category><![CDATA[Makale içeriğine göre en uygun 5 etiket: **AML targeted therapy]]></category>
		<category><![CDATA[Nrf2 pathway inhibition** **Açıklama:** 1. **AML targeted therapy:** Makalenin ana odağı AML (akut miyeloid lösemi) ve spesifik moleküler hedeflere yönelik yeni bir tedavi yakla]]></category>
		<category><![CDATA[Oxidative stress modulation]]></category>
		<category><![CDATA[Venetoclax-ML385 combination]]></category>
		<guid isPermaLink="false">https://bioengineer.org/venetoclax-plus-ml385-defeats-aml-chemotherapy-resistance/</guid>

					<description><![CDATA[In a groundbreaking advancement for acute myeloid leukemia (AML) treatment, researchers have uncovered a promising combination therapy that holds the potential to surmount chemotherapy resistance—one of the biggest obstacles in effective cancer management. This study highlights the synergistic effects of Venetoclax, a known BCL-2 inhibitor, combined with ML385, an inhibitor of the nuclear factor erythroid [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316397</post-id>	</item>
		<item>
		<title>Beyond BRCA: Decoding High-Grade Serous Ovarian Cancer</title>
		<link>https://bioengineer.org/beyond-brca-decoding-high-grade-serous-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 29 Nov 2025 10:24:31 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Chemotherapy Resistance]]></category>
		<category><![CDATA[Genomic complexity]]></category>
		<category><![CDATA[High-grade serous ovarian cancer]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[tumor evolution]]></category>
		<guid isPermaLink="false">https://bioengineer.org/beyond-brca-decoding-high-grade-serous-ovarian-cancer/</guid>

					<description><![CDATA[In the ongoing quest to understand the complexities of ovarian cancer, a groundbreaking study co-authored by Pokorna, Orlickova, Machackova, and their team sheds light on the genomic intricacies and evolutionary pathways of high-grade serous ovarian cancer (HGSOC). This study emerges in the context of an increasing demand for precision oncology, as the effectiveness of standard [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">303277</post-id>	</item>
		<item>
		<title>Researchers Identify Key Factor Driving Ovarian Cancer Metastasis</title>
		<link>https://bioengineer.org/researchers-identify-key-factor-driving-ovarian-cancer-metastasis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 15:30:08 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Chemotherapy Resistance]]></category>
		<category><![CDATA[F2R biomarker]]></category>
		<category><![CDATA[ovarian cancer metastasis]]></category>
		<category><![CDATA[protease-activated receptor 1]]></category>
		<category><![CDATA[Therapeutic Target Discovery]]></category>
		<guid isPermaLink="false">https://bioengineer.org/researchers-identify-key-factor-driving-ovarian-cancer-metastasis/</guid>

					<description><![CDATA[Researchers at the University of South Australia and the University of Adelaide have unveiled a groundbreaking biomarker and therapeutic target for ovarian cancer, offering renewed hope for women grappling with this formidable disease. Ovarian cancer, notorious for its lethality and late-stage diagnosis, remains the deadliest gynecological malignancy worldwide. Each year, ovarian cancer claims over 200,000 [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287156</post-id>	</item>
		<item>
		<title>Peptide Nanotubes: A Novel Approach to Overcoming Chemotherapy Resistance</title>
		<link>https://bioengineer.org/peptide-nanotubes-a-novel-approach-to-overcoming-chemotherapy-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 10 Oct 2025 15:33:12 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Nanomedicine]]></category>
		<category><![CDATA[Chemotherapy Resistance]]></category>
		<category><![CDATA[Doxorubicin delivery]]></category>
		<category><![CDATA[Peptide nanotubes]]></category>
		<category><![CDATA[targeted drug delivery]]></category>
		<guid isPermaLink="false">https://bioengineer.org/peptide-nanotubes-a-novel-approach-to-overcoming-chemotherapy-resistance/</guid>

					<description><![CDATA[In a breakthrough that could redefine the landscape of cancer therapeutics, researchers at the Center for Research in Biological Chemistry and Molecular Materials (CiQUS), University of Santiago de Compostela in Spain, have pioneered a novel molecular technique to enhance the intracellular delivery of anticancer drugs. Their focus is on doxorubicin, a cornerstone chemotherapy agent acclaimed [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">278796</post-id>	</item>
		<item>
		<title>Oral Cancer Organoids Uncover Insights into Chemotherapy Resistance</title>
		<link>https://bioengineer.org/oral-cancer-organoids-uncover-insights-into-chemotherapy-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 10 Jan 2025 03:24:18 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[Autophagy in Cancer]]></category>
		<category><![CDATA[Chemotherapy Resistance]]></category>
		<category><![CDATA[Minimal Residual Disease]]></category>
		<category><![CDATA[Oral Cancer Organoids]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/oral-cancer-organoids-uncover-insights-into-chemotherapy-resistance/</guid>

					<description><![CDATA[Oral cancer is a significant health challenge, with rising incidences globally, leading to over 300,000 new diagnoses each year. Among these, tongue cancer (TC) stands out due to its high prevalence and poor prognosis. Traditional treatment protocols primarily involve surgical intervention combined with chemoradiotherapy, particularly for advanced cases. However, despite these interventions, recurrence rates remain [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">233536</post-id>	</item>
	</channel>
</rss>
